CCNE1 is an inclusion criterion in 11 clinical trials for malignant solid tumor, of which 7 are open and 4 are closed. Of the trials that contain CCNE1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 9 are phase 2 (6 open) [4].

CCNE1 is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CCNE1 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CCNE1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCNE1 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and cancer as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and cervical carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCNE1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

CCNE1 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].